Patents by Inventor Stefan Klostermann
Stefan Klostermann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11952421Abstract: The present invention relates to bispecific antibodies against ROR1 and CD3, their manufacture and use.Type: GrantFiled: October 8, 2015Date of Patent: April 9, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Tanja Fauti, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Ramona Murr, Pablo Umana, Sabine Jung-Imhof, Stefan Klostermann, Michael Molhoj, Joerg Regula, Wolfgang Schaefer
-
Publication number: 20230287118Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: October 13, 2022Publication date: September 14, 2023Inventors: Oliver AST, Marina Bacac, Sabine Imhof-Jung, Christiane Neumann, Christian Klein, Stefan Klostermann, Michael Molhoj, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana
-
Patent number: 11680110Abstract: Herein is reported a method for the humanization of non-human antibodies using a structure-based scoring matrix. With the scoring matrix it is possible to determine (the requirement for and) the suitability of specific (back)mutations of amino acid residues at defined positions of a selected human germline sequence. The scoring matrix takes into account the topology, the three-dimensional structure and the interactions of the respective residue and change. Thereby the influence on antigen binding of a specific amino acid residue change can be determined.Type: GrantFiled: July 27, 2018Date of Patent: June 20, 2023Assignee: Hoffmann-La Roche Inc.Inventors: Johannes Auer, Guy Georges, Stefan Klostermann, Wolfgang Schaefer
-
Publication number: 20230068801Abstract: The present invention relates to multispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies and uses thereof.Type: ApplicationFiled: April 28, 2022Publication date: March 2, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Sabine IMHOF-JUNG, Christian KLEIN, Stefan KLOSTERMANN, Joerg Thomas REGULA, Wolfgang SCHAEFER
-
Publication number: 20220411534Abstract: The present invention generally relates to antibodies that bind to HLA-A2/WT1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.Type: ApplicationFiled: November 4, 2021Publication date: December 29, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Joerg Benz, Christian Klein, Stefan Klostermann, Ekkehard Moessner, Johannes Sam, Pablo Umaña, Lydia Jasmin Hanisch, Alexander Bujotzek, Wei Xu
-
Publication number: 20220403027Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: April 1, 2022Publication date: December 22, 2022Inventors: Oliver AST, Marina BACAC, Sabine IMHOF-JUNG, Christiane NEUMANN, Christian KLEIN, Stefan KLOSTERMANN, Michael MOLHOJ, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMANA
-
Publication number: 20220220500Abstract: Herein is reported a method for producing an IgG1 antibody by cultivating a CHO cell comprising/transfected with one or more (exogenous) nucleic acids encoding the antibody (and expressing the antibody), wherein in the nucleic acid encoding the heavy chain variable domain non-paired splice sites are removed and in the nucleic acid encoding the heavy chain constant region these are not removed.Type: ApplicationFiled: December 22, 2021Publication date: July 14, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Ulrich Goepfert, Stefan Klostermann, Katharina Lutz, Stefan Seeber
-
Publication number: 20220135672Abstract: Herein is reported an antibody binding to rabbit CD19 comprising (a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 32 or 33 or 34, (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 35 or 36, (c) a HVR-H3 comprising the amino acid sequence of SEQ ID NO: 37, (d) a HVR-L1 comprising the amino acid sequence of SEQ ID NO: 38, (e) a HVR-L2 comprising the amino acid sequence of SEQ ID NO: 39, and (f) a HVR-L3 comprising the amino acid sequence of SEQ ID NO: 40, as well as methods of using the same, especially in the identification and selection of antibody producing rabbit B-cells.Type: ApplicationFiled: June 29, 2021Publication date: May 5, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Alexander Haas, Friederike Jung, Stefan Klostermann, Sonja Offner
-
Patent number: 11192957Abstract: The present invention generally relates to antibodies that bind to HLA-A2/WT1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.Type: GrantFiled: December 20, 2018Date of Patent: December 7, 2021Assignee: Hoffmann-La Roche Inc.Inventors: Joerg Benz, Christian Klein, Stefan Klostermann, Ekkehard Moessner, Johannes Sam, Pablo Umaña, Lydia Jasmin Hanisch, Alexander Bujotzek, Wei Xu
-
Publication number: 20210309730Abstract: The present invention relates to multispecific antibodies, their manufacture and use.Type: ApplicationFiled: November 25, 2020Publication date: October 7, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Wolfgang SCHAEFER, Christian KLEIN, Sabine IMHOF-JUNG, Stefan KLOSTERMANN, Michael MOLHOJ, Joerg Thomas REGULA
-
Patent number: 11117965Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: GrantFiled: February 24, 2020Date of Patent: September 14, 2021Assignee: Hoffmann-La Roche Inc.Inventors: Oliver Ast, Marina Bacac, Sabine Imhof-Jung, Christiane Neumann, Christian Klein, Stefan Klostermann, Michael Molhoj, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana
-
Publication number: 20210230278Abstract: The present invention generally relates to antibodies that bind to HLA-A2/MAGE-A4, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.Type: ApplicationFiled: December 17, 2020Publication date: July 29, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Tina Weinzierl, Lydia Jasmin Hanisch, Alexander Bujotzek, Alejandro Carpy Gutierrez Cirlos, Stefan Klostermann, Christian Klein, Simon Patrick Keiser, Tanja Fauti, Estelle Marrer-Berger, Pablo Umaña
-
Publication number: 20210147554Abstract: The present invention relates to multispecific antibodies that bind to HLA-G ant to a T cell activating antigen, their preparation, formulations and methods of using the same.Type: ApplicationFiled: October 16, 2020Publication date: May 20, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Stefan DENGL, Sebastian FENN, Jens FISCHER, Claudia KIRSTENPFAD, Stefan KLOSTERMANN, Joerg MOELLEKEN, Georg TIEFENTHALER, Alexander BUJOTZEK, Meher MAJETY, Silke KIRCHNER
-
Publication number: 20210147553Abstract: The present invention relates to anti-HLA-G antibodies and methods of using the same.Type: ApplicationFiled: October 16, 2020Publication date: May 20, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Stefan DENGL, Sebastian FENN, Jens FISCHER, Andreas HINZ, Claudia KIRSTENPFAD, Stefan KLOSTERMANN, Joerg MOELLEKEN, Georg TIEFENTHALER, Sabine HOVES, Alexander BUJOTZEK, Meher MAJETY
-
Publication number: 20210070882Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: May 18, 2020Publication date: March 11, 2021Inventors: Marina BACAC, Christian KLEIN, Wolfgang SCHAEFER, Stefan KLOSTERMANN, Sabine IMHOF-JUNG, Michael MOLHOJ, Joerg Thomas REGULA, Pablo UMANA, Sylvia HERTER, Christiane NEUMANN
-
Publication number: 20200347147Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: July 23, 2020Publication date: November 5, 2020Inventors: Marina BACAC, Tanja FAUTI, Sabine IMHOF-JUNG, Christian KLEIN, Stefan KLOSTERMANN, Ekkehard MOESSNER, Michael MOLHOJ, Christiane NEUMANN, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMANA
-
Patent number: 10766967Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: GrantFiled: September 30, 2016Date of Patent: September 8, 2020Assignee: Hoffmann-La Roche Inc.Inventors: Marina Bacac, Tanja Fauti, Sabine Imhof-Jung, Christian Klein, Stefan Klostermann, Ekkehard Moessner, Michael Molhoj, Christiane Neumann, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana
-
Publication number: 20200231673Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: February 24, 2020Publication date: July 23, 2020Inventors: Oliver AST, Marina BACAC, Sabine IMHOF-JUNG, Christiane NEUMANN, Christian KLEIN, Stefan KLOSTERMANN, Michael MOLHOJ, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMANA
-
Publication number: 20200223945Abstract: Herein is reported a method for the humanization of non-human antibodies using a structure-based scoring matrix. With the scoring matrix it is possible to determine (the requirement for and) the suitability of specific (back)mutations of amino acid residues at defined positions of a selected human germline sequence. The scoring matrix takes into account the topology, the three-dimensional structure and the interactions of the respective residue and change. Thereby the influence on antigen binding of a specific amino acid residue change can be determined.Type: ApplicationFiled: July 27, 2018Publication date: July 16, 2020Inventors: Johannes AUER, Guy GEORGES, Stefan KLOSTERMANN, Wolfgang SCHAEFER
-
Publication number: 20200216880Abstract: Herein is reported a method for selecting a variant of a parental antibody variable domain encoding nucleic acid, wherein the parental antibody variable domain amino acid sequence encoded by said encoding nucleic acid has at least one developability hot spot, the method comprising the steps of (i) providing a multitude of DNA-containing samples (genomic material of antibody secreting B-cell) each including one or more antibody variable domain encoding nucleic acids; (ii) performing PCR amplification of said antibody variable domain encoding nucleic acids of (i) using consensus sequence-specific primers to obtain amplification products (wherein said consensus sequence-specific primers bind to consensus sequences that are common to a plurality of genes within the genetic loci set, thereby generating a pool of amplification products); (iii) sequencing a plurality of said amplification products obtained in step (ii) in order to determine the relative proportion of each nucleotide at each position in a sequencingType: ApplicationFiled: September 5, 2019Publication date: July 9, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Guy GEORGES, Stefan KLOSTERMANN, Alain TISSOT, Francesca ROS, Alexander BUJOTZEK, Clemens WRZODEK, Frederic SCHULTZ